BioCentury | Nov 21, 2020
Regulation

Nov. 20 Quick Takes: Approvals in Europe for Alnylam, Alexion therapies; plus FDA priority review for ADC, Sanofi and more

...met the primary endpoint in a Phase III trial conducted in China by its partner Edding Group Co. Ltd....
BioCentury | Dec 3, 2019
Financial News

Dec. 2 Financial Quick Takes: Kodiak gains on royalty deal; plus Clover, Aslan, Transcenta, EOC, Hui-Gene and ViGeneron

...and Everest participated in the financing. EOC is a spin-off of the oncology division of Eddingpharm...
BioCentury | Aug 21, 2019
Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

...for acute myelogenous leukemia (AML) and Phase I testing for solid tumors. Novartis AG and Eddingpharm...
BioCentury | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

...Eddingpharm gets China rights to Shionogi’s CD110 agonist Shionogi & Co. Ltd. (Tokyo: 4507) granted Eddingpharm...
...mometasone/olopatadine (gsp 301) Seven-day contraceptive patch, Twirla (AG200-15, ag-200-15, Agile Patch, estradiol/levonorgestrel) Agile Therapeutics Inc. Almirall S.A. Conatus Pharmaceuticals Inc. Edding Group Co. Ltd. Glenmark...
BioCentury | Apr 26, 2019
Company News

Lilly divests China rights to legacy antibiotics to Eddingpharm

...Vancocin vancomycin and Ceclor cefaclor, as well as a Ceclor manufacturing plant in Suzhou, to Eddingpharm...
...general manager of the Eli Lilly and Co. (NYSE:LLY) China unit, said the sale to Eddingpharm...
...would enable the pharma to further focus its resources toward launching new drugs in China. Eddingpharm...
BioCentury | Mar 13, 2018
Distillery Techniques

Biomarkers

...Chugai Pharmaceutical Co. Ltd. market Herceptin for HER2-positive breast and gastric cancers. Novartis AG and Eddingpharm...
BioCentury | Nov 10, 2017
Financial News

EOC Pharma raises $32M series B

...as did existing investor Sequoia China. EOC Pharma, a spin-off of the oncology division of Eddingpharm...
...will be used in part to in-license additional late-stage oncology assets. Zou, who was previously Eddingpharm's...
...telatinib from ACT Biotech Inc. (San Francisco, Calif.). EOC Pharma Group, Shanghai, China Jennie Walters ACT Biotech Inc. Edding Group Co. Ltd. Syndax...
BioCentury | Nov 7, 2017
Financial News

EOC Pharma raises $32M series B

...as did existing investor Sequoia China. EOC Pharma, a spin-off of the oncology division of Eddingpharm...
...will be used in part to in-license additional late-stage oncology assets. Zou, who was previously Eddingpharm's...
...NASDAQ:SNDX), and worldwide rights to telatinib from ACT Biotech Inc. (San Francisco, Calif.). Jennie Walters telatinib ACT Biotech Inc. Edding Group Co. Ltd. Syndax...
BioCentury | Sep 8, 2017
Company News

Lilly revamping presence in China

...the pharma's diabetes drug Humulin , a recombinant biosynthetic insulin. In November 2016, Lilly granted Eddingpharm...
...units would be responsible for commercialization in China (see BioCentury Extra, Jan. 5) . Chris Lieu Ceclor Humulin Vancocin 3SBio Inc. Edding Group Co. Ltd. Eli...
BioCentury | Sep 8, 2017
Company News

Lilly revamping presence in China

...the pharma's diabetes drug Humulin , a recombinant biosynthetic insulin. In November 2016, Lilly granted Eddingpharm...
...responsible for commercialization in China. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Pharmaceuticals Chris Lieu Ceclor Humulin Vancocin 3SBio Inc. Edding Group Co. Ltd. Eli...
Items per page:
1 - 10 of 48
BioCentury | Nov 21, 2020
Regulation

Nov. 20 Quick Takes: Approvals in Europe for Alnylam, Alexion therapies; plus FDA priority review for ADC, Sanofi and more

...met the primary endpoint in a Phase III trial conducted in China by its partner Edding Group Co. Ltd....
BioCentury | Dec 3, 2019
Financial News

Dec. 2 Financial Quick Takes: Kodiak gains on royalty deal; plus Clover, Aslan, Transcenta, EOC, Hui-Gene and ViGeneron

...and Everest participated in the financing. EOC is a spin-off of the oncology division of Eddingpharm...
BioCentury | Aug 21, 2019
Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

...for acute myelogenous leukemia (AML) and Phase I testing for solid tumors. Novartis AG and Eddingpharm...
BioCentury | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

...Eddingpharm gets China rights to Shionogi’s CD110 agonist Shionogi & Co. Ltd. (Tokyo: 4507) granted Eddingpharm...
...mometasone/olopatadine (gsp 301) Seven-day contraceptive patch, Twirla (AG200-15, ag-200-15, Agile Patch, estradiol/levonorgestrel) Agile Therapeutics Inc. Almirall S.A. Conatus Pharmaceuticals Inc. Edding Group Co. Ltd. Glenmark...
BioCentury | Apr 26, 2019
Company News

Lilly divests China rights to legacy antibiotics to Eddingpharm

...Vancocin vancomycin and Ceclor cefaclor, as well as a Ceclor manufacturing plant in Suzhou, to Eddingpharm...
...general manager of the Eli Lilly and Co. (NYSE:LLY) China unit, said the sale to Eddingpharm...
...would enable the pharma to further focus its resources toward launching new drugs in China. Eddingpharm...
BioCentury | Mar 13, 2018
Distillery Techniques

Biomarkers

...Chugai Pharmaceutical Co. Ltd. market Herceptin for HER2-positive breast and gastric cancers. Novartis AG and Eddingpharm...
BioCentury | Nov 10, 2017
Financial News

EOC Pharma raises $32M series B

...as did existing investor Sequoia China. EOC Pharma, a spin-off of the oncology division of Eddingpharm...
...will be used in part to in-license additional late-stage oncology assets. Zou, who was previously Eddingpharm's...
...telatinib from ACT Biotech Inc. (San Francisco, Calif.). EOC Pharma Group, Shanghai, China Jennie Walters ACT Biotech Inc. Edding Group Co. Ltd. Syndax...
BioCentury | Nov 7, 2017
Financial News

EOC Pharma raises $32M series B

...as did existing investor Sequoia China. EOC Pharma, a spin-off of the oncology division of Eddingpharm...
...will be used in part to in-license additional late-stage oncology assets. Zou, who was previously Eddingpharm's...
...NASDAQ:SNDX), and worldwide rights to telatinib from ACT Biotech Inc. (San Francisco, Calif.). Jennie Walters telatinib ACT Biotech Inc. Edding Group Co. Ltd. Syndax...
BioCentury | Sep 8, 2017
Company News

Lilly revamping presence in China

...the pharma's diabetes drug Humulin , a recombinant biosynthetic insulin. In November 2016, Lilly granted Eddingpharm...
...units would be responsible for commercialization in China (see BioCentury Extra, Jan. 5) . Chris Lieu Ceclor Humulin Vancocin 3SBio Inc. Edding Group Co. Ltd. Eli...
BioCentury | Sep 8, 2017
Company News

Lilly revamping presence in China

...the pharma's diabetes drug Humulin , a recombinant biosynthetic insulin. In November 2016, Lilly granted Eddingpharm...
...responsible for commercialization in China. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Pharmaceuticals Chris Lieu Ceclor Humulin Vancocin 3SBio Inc. Edding Group Co. Ltd. Eli...
Items per page:
1 - 10 of 48